PLC Systems Inc., a company focused on cardiac and vascular medical device-based technologies, announced the appointment of Dr. Louis Brenner to the Company’s Board of Directors. Dr. Brenner, currently Senior Vice President of AMAG Pharmaceuticals, Inc., replaced former board member Alan Magazine. Dr. Brenner holds a B.S. degree in Biology from Yale College, an M.D. degree from Duke University School of Medicine, and an M.B.A. degree from Harvard Business School. Additionally, he is board certified in Nephrology and Internal Medicine and cares for patients with kidney disease at Brigham and Women’s Hospital in Boston. Dr. Brenner has published on a variety of Nephrology topics in leading scientific journals.

Dr. Brenner, 39, brings expertise to the development and commercialization of clinically innovative technologies. At AMAG Pharmaceuticals, he has played a key role in the progress of the company’s lead product candidate. Prior to joining AMAG Pharmaceuticals, he spent four years at Genzyme Corporation, where he served as the Senior Director of Business Development for the Renal and Transplantation Units. He is currently the Chairman of the Board of the National Kidney Foundation.

Mark R. Tauscher, President and Chief Executive Officer of PLC Systems, said, “We are very pleased to welcome Lou to our Board. His strong business experience in our sector adds a vital voice to our strategic planning. His expertise in Nephrology and continued work in this field will bolster our efforts to expand the launch of our innovative RenalGuard® technology, which is targeted at patients with diminished renal function who are undergoing imaging procedures. We look forward to his contributions to our Company’s continued progress.”